Price (delayed)
$3.04
Market cap
$86.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.9
Enterprise value
$57.69M
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular
There are no recent dividends present for IMDX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.